Cymabay Therapeutics Stock News

CymaBay Therapeutics, Inc. (NASDAQ:CBAY ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Dan Menold -

NEWARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea

CBAY earnings call for the period ending December 31, 2021.

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q4 2021 Results - Earnings Call Transcript

NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic d

Conference call and webcast today at 4:30 p.m. ET Conference call and webcast today at 4:30 p.m. ET

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis AbbVie, Inc. (NYSE: ABBV) announced 

CymaBay Therapeutics (NASDAQ:CBAY) is scheduled to announce Q4 earnings results on Thursday, March 17th, after market close.The consensus EPS Estimate is -$0.20 (+13.0% Y/Y) and…

NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic d

NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 17, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2021 and to provide a business update.

NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dis

NEWARK, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dise

Gainers: Integral Ad Science (IAS) +14%, Anavex Life Sciences (AVXL) +8%, Algoma Steel (ASTL) +5%, EMCORE (EMKR) +4%, CymaBay Therapeutics (CBAY) +4%.Losers: Apyx Medical (APYX)

Microbot Medical (MBOT) +10%. CymaBay Therapeutics (CBAY) +9%. Aptorum (APM) -13%. G Medical Innovations (GMVD) -11%.